Physician profile
Mark W Schaar
NPI 1932180148
$16,362.02
in general payments reported to CMS, 2019-2025
64 companies · $2,078 in 2025
The $2,078 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,223 · 2020: $1,427 · 2021: $3,013 · 2022: $2,710 · 2023: $2,264 · 2024: $2,647 · 2025: $2,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,988.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,988.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,611.91 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,598.29 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Glaxosmithkline, LLC. | $1,378.67 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $1,218.12 | 2019-2025 | Otezla, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $1,090.22 | 2020-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Pfizer INC. | $919.26 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $885.61 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $677.38 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Axsome Therapeutics, INC. | $616.99 | 2023-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $400.36 | 2022-2024 | Caplyta |
| Allergan, INC. | $400.28 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $365.10 | 2019-2025 | Capvaxive, Gardasil 9, Zerbaxa |
| Teva Pharmaceuticals USA, INC. | $333.42 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $287.84 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $281.01 | 2021 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Schaar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.